Substance-related Disorders

July 4th invites celebration, typically with alcohol. Try our quiz based on a review of the holiday drinking patterns of US adults. Are answers to these 10 questions what you expect?

Your daily dose of the clinical news you may have missed.

Cebranopadol developer Tris Pharma expects to submit an NDA to the FDA for the dual-NMR agonist to treat moderate-to-severe acute pain later this year.

The novel dual NMR agonist was scored significantly less "likable" when crushed and taken intranasally compared with oxycodone, the company reported.

The DEA action includes 3 new telehealth rules that make permanent several flexibilities enacted during the pandemic and also establish new protections for patients.

Among GPs, IMs, FPs, the primary reason for reluctance to treat addiction is lack of support in the "institutional environment," followed by concerns over personal skills.

Your daily dose of the clinical news you may have missed.

The 3% decline in 2023 compared with 2022 is "heartening news," CDC's Houry says, but the mission is far from accomplished.

Access to methadone and buprenorphine treatment may be easier and incentive to continue treatment could start at home, using telehealth, according to HHS.

The investigational combination opioid from Ensysce Biosciences is designed to deter abuse as well as prevent accidental or intentional overdose, the company said.